TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations ...
Briumvi shows increasing revenues but faces decelerating growth, suggesting possible market saturation or increased competition. TG Therapeutics has a strong balance sheet but contends with high SG&A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback